# Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

> **NCT01836549** · PHASE2 · TERMINATED · sponsor: **Pediatric Brain Tumor Consortium** · enrollment: 43 (actual)

## Conditions studied

- Anaplastic Astrocytoma
- Anaplastic Ependymoma
- Astrocytoma, Grade II
- Ependymoma
- Giant Cell Glioblastoma
- Glioblastoma
- Gliosarcoma
- Oligodendroglioma
- Brainstem Tumors

## Interventions

- **DRUG:** imetelstat sodium

## Key facts

- **NCT ID:** NCT01836549
- **Lead sponsor:** Pediatric Brain Tumor Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Due to several intracranial hemorrhages and recommendation by the PBTC DSMB.
- **Last updated:** 2018-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01836549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01836549, "Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01836549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*